{{Rsnum
|rsid=12051723
|Gene=RNF213
|Chromosome=17
|position=80350459
|Orientation=plus
|GMAF=0.14
|Gene_s=RNF213
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 64.6 | 28.3 | 7.1
| HCB | 55.5 | 37.2 | 7.3
| JPT | 72.6 | 23.9 | 3.5
| YRI | 100.0 | 0.0 | 0.0
| ASW | 94.7 | 5.3 | 0.0
| CHB | 55.5 | 37.2 | 7.3
| CHD | 59.6 | 35.8 | 4.6
| GIH | 76.2 | 22.8 | 1.0
| LWK | 98.2 | 1.8 | 0.0
| MEX | 87.9 | 12.1 | 0.0
| MKK | 99.4 | 0.6 | 0.0
| TSI | 76.5 | 20.6 | 2.9
| HapMapRevision=28
}}{{PMID Auto GWAS
  |PMID=23118302
  |Trait=Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
  |Title=Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
  |RiskAllele=T
  |Pval=3E-6
  |OR=2.20
  |ORtxt=[1.22-3.18] percent increase
  }}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}